• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Melissa Johnson Underscores the Need for Lung Cancer Screening Guidance for Never-Smokers

Video

Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon, discusses the need for increased lung cancer screening among patients who have no tobacco use history.

We currently do not have a system in place for screening never-smokers for lung cancer, explained Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon.

Transcript

Is enough being done to identify patients who should be screened for lung cancer, including never-smokers?

We know that screening patients for lung cancers decreases the number of patients being diagnosed with lung cancer each year. The problem is that the [National Lung Screening Trial] data is not always generalizable to all patients. You mentioned the never-smokers. It's a really good question. We don't have a mechanism for screening never-smokers. Just in 2021, we have decreased the number of pack-years required from 30 pack-years to 20 pack-years and decreased the age from 55 to 50 for patients to make them eligible for screening. And so those are steps in the right direction. But we'll never get to never-smokers if we're just looking for patients that have a tobacco screening history. In parts of the world such as Asia, 50% of lung cancer patients will be never-smokers. And so that shows us that our current ways of selecting patients (ie, their tobacco exposure history) are neither sufficient nor far-reaching enough to really be identifying those patients most at risk because they're not thinking about it.

Related Videos
Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center.
Debra Boyer, MD, MHPE, ATSF.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Plasminogen is vital in the body's coagulation process and breaking down clots | image credit: peterschreiber.media - stock.adobe.com
ISPOR 2024 Recap
Chris Pagnani, MD, PC
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.